NVS - ノバルティス ()

NVSのニュース

   STAT+: Novartis suspends production of two cancer therapies over potential quality issues  2022/05/05 20:46:29 STAT News
Due to manufacturing issues, Novartis has voluntarily suspended production of two therapies that use nuclear medicine to target and treat cancer cells.
   Novartis suspends production of two cancer therapies over potential quality issues  2022/05/05 20:46:29 STAT News
The company makes the medicines at facilities in New Jersey and Italy. Novartis expects to resume some supplies in the next six weeks.
   Novartis halts radioligand therapy production in U.S. and Italy over quality issues  2022/05/05 18:13:11 Seeking Alpha
Novartis (NVS) (NVSEF) announced on Thursday that the company decided to pause production at its radioligand therapy manufacturing sites in Ivrea, Italy, and Millburn, New Jersey,…
   Novartis suspends delivery of cancer treatment as it address potential production issues  2022/05/05 17:37:23 MarketWatch
The U.S.-listed shares of Novartis AG fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was "temporarily" suspending delivery of its cancer treatments Lutathera and Pluvicto in the U.S., as part of a quality review of its production sites in Millburn, New Jersey and Ivrea, Italy. The delivery suspension follows the company''s "temporary, voluntary suspension" of production of its radioligand therapy production sites in New Jersey and Italy, which is due to "an abundance of caution" while it addresses potential quality issues identified in its manufacturing process. The company said it is also putting a temporary hold on screening and enrollment for clinical trials of its cancer treatment Lu-PSMA-617. "Novartis takes this very seriously and the company is doing everything it can to resolve this issue and resume patient doses as quickly as possible," Novartis stated. "Health authorities have been informed and will receive additional updates as they are available." The stock has slipped 1.7% year to date, while the S&P 500 has shed 12.8%.
   Novartis suspends two cancer therapies over quality concerns  2022/05/05 16:30:23 Financial Post
ZURICH — Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing. “Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply […]
   Novartis Q2 2021 Earnings Preview  2021/07/20 15:46:19 Seeking Alpha
   Novartis Pharma AG: Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity  2021/07/20 11:17:00 FinanzNachrichten
Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and
   Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity  2021/07/20 11:05:00 Intrado Digital Media
Basel, July 20, 2021 Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the root causes of systemic disparities in health outcomes and create greater diversity, equity and inclusion across the research and development ecosystem.
   Diabetic Nephropathy Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Analysis, Forecast Report  2021/07/20 09:56:00 Intrado Digital Media
Top Players Covered in the Diabetic Nephropathy Market Research Report are Merck & Co., Inc., Abbott, Pfizer Inc., Siemens, Novartis AG, GENERAL ELECTRIC COMPANY, Bayer AG, Mitsubishi Tanabe Pharma Corporation, Renata Limited, and others. and other key market players Top Players Covered in the Diabetic Nephropathy Market Research Report are Merck & Co., Inc., Abbott, Pfizer Inc., Siemens, Novartis AG, GENERAL ELECTRIC COMPANY, Bayer AG, Mitsubishi Tanabe Pharma Corporation, Renata Limited, and others. and other key market players
   Insights on the Losartan Global Market to 2026 - Featuring Pfizer, Teva Pharmaceutical Industries and Sanofi Among Others  2021/07/20 07:53:00 Intrado Digital Media
Dublin, July 20, 2021 (GLOBE NEWSWIRE) -- The "Global Losartan Market, By Source (Contract Manufacturing Organizations, In-House), By Form (Tablet, Powder), By Strength (25mg, 50mg, 100mg, Others), By Distribution Channel (Offline, Online), By Application, By End-User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The Global Losartan Market was valued at $4.73 billion in 2020 and is expected to grow at a formidable rate of 7.81% during the forecast period. The Global Losartan Market is driven by the growing prevalence of hypertension, stroke and diabetic nephropathy across the world. Losartan is a medication that is used to treat high blood pressure. Furthermore, losartan is widely used in slowing down long-term kidney damage due to type II diabetes which is further expected to propel the market growth through 2026. The sudden outbreak and spread of the COVID-19 pandemic has resulted in the loss of jobs for many people due to which the level of anxiety and hypertension has increased among the people.
   FinTech Market 2021- PolicyGenius, EquityZen, Quovo, Novus  2021/06/30 12:00:00 Jumbo News
The Global FinTech Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2025. The FinTech Market report is a valuable source of insightful data for business strategists. It offers the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The report explores the current outlook in global and key regions []
   Novus Innovation Corridor Achieves National Sustainability Recognition  2021/06/29 19:29:40 Gteater Phoenix In Business
In a first for Arizona, the Novus Innovation Corridor earned LEED-ND Gold certification last month from the U.S. Green Building Council. Novus, the 355-acre mixed-use, public-private partnership between Arizona State University and Catellus Development Corporation adjacent to the ASU Tempe campus, is the first LEED-ND community certified at any level in Arizona. This is a [More] The post Novus Innovation Corridor Achieves National Sustainability Recognition appeared first on Greater Phoenix In Business Magazine .
   iConnections Deepens Analytics and Data Offerings with Novus Partnership  2021/06/24 13:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--iConnections, the industry-leading platform and community that seamlessly connects investment managers and allocators, today announced that it is partnering with Novus, the leading portfolio intelligence platform, allowing managers and allocators to access Novus data and analytics through the iConnections platform. iConnections members will be able to access Novus research, including manager league tables, the Novus 4C indices (tracking important hedge fund holdings
   Swedish PM Lofven remains publics top choice despite losing no-confidence vote RT World News  2021/06/24 10:39:05 State Of Press
Swedish Prime Minister Stefan Lofven is still the countrys most popular leader, according to a poll released on Thursday, amid an ongoing political crisis following a no-confidence vote in parliament earlier this week. A Novus poll conducted in the wake of the no-confidence vote found that 38% of Swedish voters still have faith in Lofven,
   Swedish PM Lofven still voters favourite leader despite crisis  2021/06/24 08:07:43 Metro US
STOCKHOLM (Reuters) Social Democrat Prime Minister Stefan Lofven is Swedish voters most trusted leader, a poll showed on Thursday, despite a crisis that saw parliament pass a vote of no-confidence in him at the start of the week. The Novus poll showed 38% of Swedes have confidence in Lofven, ahead of his most likely Read More

calendar